Last reviewed · How we verify
HRS-2261 oral tablet
HRS-2261 oral tablet is a Small molecule drug developed by Guangdong Hengrui Pharmaceutical Co., Ltd. It is currently in Phase 2 development.
At a glance
| Generic name | HRS-2261 oral tablet |
|---|---|
| Sponsor | Guangdong Hengrui Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough (PHASE2)
- A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-2261 oral tablet CI brief — competitive landscape report
- HRS-2261 oral tablet updates RSS · CI watch RSS
- Guangdong Hengrui Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about HRS-2261 oral tablet
What is HRS-2261 oral tablet?
HRS-2261 oral tablet is a Small molecule drug developed by Guangdong Hengrui Pharmaceutical Co., Ltd.
Who makes HRS-2261 oral tablet?
HRS-2261 oral tablet is developed by Guangdong Hengrui Pharmaceutical Co., Ltd (see full Guangdong Hengrui Pharmaceutical Co., Ltd pipeline at /company/guangdong-hengrui-pharmaceutical-co-ltd).
What development phase is HRS-2261 oral tablet in?
HRS-2261 oral tablet is in Phase 2.